A total of 957 patients with intermediate - or high-risk Ta T1 ( without carcinoma in situ ) NMIBC were randomized in European Organization for Research and Treatment of Cancer ( EORTC ) trial 30911 comparing six weekly instillations of epirubicin , BCG , and BCG plus isoniazid followed by three weekly maintenance instillations over 3 yr .